Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Other Non-Current Liabilities (2022 - 2025)

Vivos Therapeutics has reported Other Non-Current Liabilities over the past 3 years, most recently at $1.3 million for Q4 2025.

  • Quarterly Other Non-Current Liabilities changed N/A to $1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Dec 2025, changed N/A year-over-year, with the annual reading at $1.3 million for FY2025, N/A changed from the prior year.
  • Other Non-Current Liabilities was $1.3 million for Q4 2025 at Vivos Therapeutics, down from $1.4 million in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $2.2 million in Q2 2023 and troughed at $101000.0 in Q1 2022.
  • The 3-year median for Other Non-Current Liabilities is $1.3 million (2023), against an average of $1.2 million.
  • The largest YoY upside for Other Non-Current Liabilities was 1219.8% in 2023 against a maximum downside of 1219.8% in 2023.
  • A 3-year view of Other Non-Current Liabilities shows it stood at $101000.0 in 2022, then soared by 494.06% to $600000.0 in 2023, then surged by 116.67% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Other Non-Current Liabilities are $1.3 million (Q4 2025), $1.4 million (Q3 2025), and $1.4 million (Q2 2025).